GANX
Gain Therapeutics Inc

2,123
Mkt Cap
$99.27M
Volume
1.52M
52W High
$3.06
52W Low
$1.41
PE Ratio
-4.30
GANX Fundamentals
Price
$2.85
Prev Close
$2.75
Open
$2.75
50D MA
$2.00
Beta
1.20
Avg. Volume
891,125.22
EPS (Annual)
-$0.892
P/B
16.74
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Equities Analysts Set Expectations for GANX FY2025 Earnings
Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Equities research analysts at Roth Capital raised their FY2025 earnings per share estimates for Gain Therapeutics in a note issued to investors...
MarketBeat·4d ago
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Releases Earnings Results, Meets Estimates
Gain Therapeutics (NASDAQ:GANX - Get Free Report) released its earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of...
MarketBeat·7d ago
News Placeholder
Gain Therapeutics' GT-02287 study to deliver positive findings, says Roth MKM
Gain Therapeutics' GT-02287 study to deliver positive findings, says Roth MKM...
Yahoo! Finance: News·11mo ago
News Placeholder
Optimistic Outlook for Gain Therapeutics Amid Progress of GT-02287 and Successful Financing
Maxim Group analyst Jason McCarthy has maintained their bullish stance on GANX stock, giving a Buy rating today. Jason McCarthy's rating is based o...
TipRanks Financial Blog·1y ago
News Placeholder
Gain Therapeutics Advances Parkinson's Treatment in Phase 1
The latest update is out from Gain Therapeutics (GANX). Gain Therapeutics, Inc. has successfully completed the multiple ascending dose phase of its...
TipRanks Financial Blog·1y ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Director Jeffrey Scott Riley Acquires 30,000 Shares
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business's stock in a transaction on Thursday, March 28th. The shares were acquired at...
Ticker Report·2y ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 156,700 shares, an...
Ticker Report·2y ago
News Placeholder
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
Related Stocks: GANX...
GuruFocus·2y ago
News Placeholder
Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson's Treatment and Solid Financial Outlook
Gain Therapeutics (GANX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...
TipRanks Financial Blog·2y ago

Latest GANX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.